Quick summary
- Mechanism: Wegovy is a GLP-1 receptor agonist (semaglutide). Mounjaro is a dual GIP/GLP-1 receptor agonist (tirzepatide).
- Average results: Trials show tirzepatide often leads to greater average weight loss than semaglutide 2.4 mg when both are titrated and combined with lifestyle changes.
- Tolerability: Both commonly cause temporary GI side effects during dose escalation; slow titration and dietary changes help.
- Access in Australia: Wegovy is approved for chronic weight management; Mounjaro is approved for type 2 diabetes and may be considered for weight management at clinician discretion. Availability and pricing vary.
- Best fit: Consider medical history, response, side-effect tolerance, supply, cost and personal goals. A supervised plan is essential.
Mounjaro vs Wegovy: how they work
Wegovy (semaglutide) is a GLP-1 receptor agonist. It slows gastric emptying, reduces appetite and improves glycaemic control. Mounjaro (tirzepatide) is a dual agonist that activates GIP and GLP-1 receptors. The dual mechanism may further impact appetite regulation and metabolic signalling.
- Wegovy: semaglutide 2.4 mg once weekly
- Mounjaro: tirzepatide 2.5–15 mg once weekly
Effectiveness: average weight loss vs real‑world fit
Large trials report meaningful average weight loss for both medicines with lifestyle support. Head‑to‑head evidence suggests tirzepatide produces greater average reductions than semaglutide 2.4 mg for many patients when titrated to higher doses.
- Semaglutide 2.4 mg (Wegovy): ~15% average weight loss at ~68 weeks in non‑diabetic adults when combined with lifestyle intervention.
- Tirzepatide (Mounjaro): ~15–21% average weight loss at ~72 weeks in non‑diabetic adults in trials using 5–15 mg, with lifestyle intervention; head‑to‑head data show superiority vs semaglutide 2.4 mg on average.
Individual response varies. Tolerability and dose reached often determine results. Physician‑guided escalation, nutrition and activity remain critical.
Dosing and titration schedules
Both are weekly injections with gradual dose increases to reduce side effects. If side effects occur, clinicians often pause or step back a dose before resuming.
- Wegovy common path: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly (step up roughly every 4 weeks as tolerated).
- Mounjaro common path: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly (step up roughly every 4 weeks as tolerated).
Exact schedules may differ based on medical history and side‑effect response.
Side effects and safety
The most common reactions for both are gastrointestinal—nausea, vomiting, diarrhoea or constipation, abdominal discomfort, reflux, reduced appetite and fatigue—especially during dose escalation.
- Warnings: pancreatitis, gallbladder disease, acute kidney injury (usually secondary to dehydration), potential risk of thyroid C‑cell tumours seen in rodents (human relevance uncertain). Do not use with a personal/family history of medullary thyroid carcinoma (MTC) or MEN2.
- Drug interactions and comorbidities require review (e.g., insulin/sulfonylurea dose adjustments, prior pancreatitis, severe GI disease).
- Pregnancy/breastfeeding: discuss contraception and planning; these medicines are generally not used during pregnancy.
Managing side effects: slower titration, smaller meals, lower fat intake, hydration, and pausing escalation often help.
Who each option may suit
- Consider Wegovy if you want an on‑label weight‑management medicine with established GLP‑1 evidence, and you tolerate semaglutide well.
- Consider Mounjaro if your clinician believes the dual GIP/GLP‑1 approach and dose range may better match your goals and medical profile, or you have not achieved adequate results or tolerability with semaglutide.
- Either option requires a comprehensive plan: nutrition, resistance training, sleep and ongoing follow‑up to sustain results.
Access in Australia: approvals, PBS and availability
- Wegovy: TGA‑registered for chronic weight management in adults meeting criteria. Supply has varied. Not PBS‑listed for obesity at the time of writing; confirm current status.
- Mounjaro: TGA‑registered for type 2 diabetes. Weight‑loss prescribing may occur at a prescriber’s discretion where appropriate. PBS and pricing differ for diabetes vs obesity. Confirm current availability and costs locally.
- Supply: Both medicines have experienced intermittent shortages. Your clinician can advise on practical access and alternatives.
Eligibility criteria, documentation and ongoing monitoring are usually required.
Mounjaro prescription in Australia Wegovy prescription in Australia
Cost: what affects out‑of‑pocket price
Out‑of‑pocket cost depends on indication (diabetes vs obesity), dose strength, pharmacy supply and any PBS subsidy applicable to your situation. Wegovy for obesity is generally private cost. For current price ranges and cost drivers, see:
Practical differences you may notice
- Pen strengths and steps: Wegovy typically uses single‑dose pens across 0.25–2.4 mg; Mounjaro uses single‑dose pens across 2.5–15 mg.
- Escalation timing: both usually step every 4 weeks; clinicians adjust pacing to tolerability.
- Response patterns: some patients respond better to one medicine’s mechanism; previous GLP‑1 experience may inform choice.
- Supply and continuity: your best option may be influenced by current stock and refill reliability.
Decision guide: Wegovy or Mounjaro?
- If you want on‑label weight‑management use and tolerate GLP‑1s well → discuss Wegovy first, check supply and cost.
- If you need more weight loss on average or had limited response to semaglutide → discuss tirzepatide dosing and tolerability.
- If side effects limit dose escalation → consider slower titration, GI strategies, or switching after clinical review.
- Always factor in comorbidities, other medicines, pregnancy plans and long‑term maintenance strategy.
Frequently asked questions
Which is better for weight loss: Mounjaro or Wegovy?
On average, tirzepatide shows greater weight reduction than semaglutide 2.4 mg in head‑to‑head research. Individual results vary; the best choice balances efficacy, side effects, access and cost.
How long until I notice changes?
Many people notice appetite changes within 1–3 weeks. Clinically significant weight changes typically accumulate over months as doses increase and lifestyle changes are maintained.
Will I regain weight if I stop?
Weight regain is common if the medicine is stopped without a maintenance plan. Behavioural strategies and ongoing medical guidance are key to sustaining results.
Can I drink alcohol while using these medicines?
Moderation is advised. Alcohol can worsen GI symptoms, add calories and affect glycaemia for some. Discuss specifics with your prescriber.
Is one safer than the other?
Both have similar class warnings and side‑effect profiles. Safety depends on your history, other medicines and dose. Review risks with your clinician.
Are these suitable for PCOS or insulin resistance?
GLP‑1–based therapies are being used for weight management in people with insulin resistance and PCOS under medical supervision. Suitability is case‑by‑case.
Next steps: speak with a qualified prescriber
Choosing between Mounjaro and Wegovy is best done with a clinician who can weigh your medical history, goals, side‑effect tolerance, access and cost. A short intake helps determine eligibility and a safe titration plan.
Get personalised guidance
Complete this form to request help comparing Mounjaro and Wegovy, check eligibility and discuss access and costs in Australia.
Urgent symptoms? Seek immediate medical care. Do not wait for an online reply.
Final takeaway
Wegovy and Mounjaro are both effective weekly injections used in weight‑management care. Tirzepatide often yields greater average weight loss than semaglutide 2.4 mg, but the right choice depends on your medical history, tolerability, access and budget. Work with a clinician to select and titrate safely—and pair treatment with sustainable nutrition, resistance training and sleep to maintain results.